GOA: Molbio Diagnostics, a pioneer in global healthcare based in Goa, is proud to announce the appointment of two new Independent Directors to its board, Professor (Dr.) Balram Bhargava and Dr. Arun Kumar Jha. These appointments come as the company continues to strengthen its Leadership and make significant strides in healthcare accessibility with its innovative solutions that cater to the remotest regions globally.

Professor (Dr.) Balram Bhargava is a leader in the public health sector with over 35 years of experience in medical research and health system strengthening. His previous roles include Director-General of the Indian Council of Medical Research and Secretary of India’s Department of Health Research, being at the forefront of managing several public health crises in India. Dr. Bhargava’s ongoing work in pandemic preparedness and health policy has been instrumental in promoting affordable healthcare innovations. His leadership at the National Academy of Sciences and numerous other institutions showcases his commitment to enhancing health outcomes worldwide.

“I am honored to join the board of Molbio Diagnostics, a company that is at the forefront of diagnostic innovation and global health impact. The opportunity to contribute to Molbio’s mission aligns perfectly with my lifelong commitment to enhancing health through affordable and accessible healthcare solutions. I look forward to bringing my experience in medical research and health policy to further Molbio’s efforts in revolutionizing point-of-care diagnostics and advancing global healthcare standards,” said Professor (Dr.) Bhargava.

Dr. Arun Kumar Jha brings a wealth of experience in public health and policy, including his role as an Adviser in the Department of Economic Affairs, Ministry of Finance, and as an Economic Adviser in the Department of Health & Family Welfare, Ministry of Health & Family Welfare. He is currently working as the Hon’ble Chancellor of the National Institute of Advanced Manufacturing Technology (NIAMT) and Senior Adviser in John Snow India Pvt. Ltd. With his active involvement with the Government of India in schemes and programs that focus on tuberculosis elimination in the country, Dr. Jha has recently signed up an assignment with the Stop TB Partnership and United Nations Office for Project Services (UNOPS), positioning him as an invaluable asset in advancing Molbio’s mission to support global health initiatives.

“Joining Molbio Diagnostics as an Independent Director is a significant step in my continued advocacy for public health and policy reform. With Molbio’s innovative Truenat® platform, I see a tremendous potential to bridge healthcare gaps and improve disease management worldwide,” Dr. Jha expressed his enthusiasm. “Looking forward to being part of this transformative journey and supporting Molbio’s strategic vision in making a lasting impact on global health, particularly in underserved regions

“These appointments reflect Molbio Diagnostics’ commitment to bringing on board leaders who are at the forefront of healthcare innovation and public health policy,” said Sriram Natarajan, Director and CEO of Molbio Diagnostics. “Dr. Jha and Dr. Bhargava’s impressive backgrounds and shared dedication to improving healthcare access aligns perfectly with our vision of transforming global health landscapes.”

Molbio Diagnostics remains dedicated to its mission of enhancing healthcare accessibility through innovative diagnostics solutions. The inclusion of Dr. Jha and Dr. Bhargava on the board is expected to further strengthen the company’s impact on global health.

The post Molbio Diagnostics Expands Board with Renowned Public Health Advocates appeared first on NRI News.

BENGALURU: MedGenome, a leading global Genomic Diagnostic and Research Services company in South Asia, becomes the first to offer advanced genomics services using Illumina’s NovaSeq X Plus in South Asia. With this, the company anticipates bringing down the reagent cost of Human Whole Genome sequencing to USD $200 in the near future. In conjunction with this acquisition, MedGenome is thrilled to launch KaryoSeq (or Karyotype Sequencing), an innovative Whole Genome Sequencing to diagnose prenatal and newborn conditions.

The NovaSeq X Series is Illumina’s most powerful sequencing system. With the ability to generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers at a shorter turnaround time, this latest sequencer is aimed at making genomics more sustainable and accessible to more people globally. MedGenome has had a long-standing partnership with Illumina over the last decade expanding its portfolio of sequencing equipment with the latest offerings and becoming a leader in adopting the most up-to-date sequencing technology. NovaSeq X Plus promises to accelerate a deeper understanding of genetic disorders and can perform a broad range of data-intensive applications, bringing more breakthroughs in genetic disease diagnosis and treatment.

MedGenome has launched several breakthrough tests in key disease areas in the last few years. The latest offering, KaryoSeq has significant advantages over traditional cytogenetic and molecular techniques. The test is a faster and more accurate solution that allows for the detection of small chromosomal abnormalities, such as microdeletions or microduplications, that may not be easily identified through microscopic examination alone. It is recommended for individuals with suspected or confirmed genetic disorders or an increased risk of carrying chromosomal abnormalities, aiming to provide precise and rapid results, and helping clinicians and families make informed decisions about inherent genetic conditions.

Dr Vedam Ramprasad, Ph.D., CEO of, MedGenome said, “As pioneers in genetic testing with a deep focus on scientific innovation and research, bringing NovaSeq X Plus in India will help us in making faster and accurate diagnosis. The launch of KaryoSeq further marks a significant milestone in the field of prenatal and newborn genetic testing in this part of the world, empowering clinicians with accurate and comprehensive genetic information. Traditionally, the cost has played a major factor in penetrating the genetic testing market. MedGenome has been striving to make these tests affordable to the masses while adhering to global quality standards.  MedGenome’s KaryoSeq test is another step in this direction. The test is cost-effective while providing superior diagnostic yield and accuracy in identifying deletions and gains as small as 1 megabase (1 million DNA base pairs).”

MedGenome offers an extensive range of over 1300 advanced genetic tests covering various disease categories. With a CAP-accredited genetic testing laboratory in India and a high-throughput Next-Generation Sequencing lab in Foster City, California, the company has established itself as a prominent player in the field. Notably, MedGenome has developed the largest database of South Asian genetic variants through its expertise in genetic diagnostics, research collaborations, and its role as a co-founding member of GenomeAsia 100K. Serving more than 3,50,000 families through a network of over 4,000 hospitals and over 11,000 clinicians across India, MedGenome provides comprehensive genetic testing services and makes significant contributions to the field of genomics, and continues to revolutionize the healthcare space with its path-breaking genomics solutions.

The post MedGenome acquires Illumina’s NovaSeq X Plus and Launches Genome Sequencing Test KaryoSeq appeared first on NRI News.